Capecitabine-d₁₁ 

Capecitabine-d₁₁ is the deuterium labeled Capecitabine. Capecitabine is an oral proagent that is converted to its active metabolite, 5-FU, by thymidine phosphorylase[1][2].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

370.42

C₁₅H₁₁D₁₁FN₃O₆

1132662-08-8

Solid

White to off-white

C[C@@H]1[C@H]([C@H]([C@H](N2C(N=C(C(F)=C2)NC(OC([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=O)=O)O1)O)O

Room temperature in continental US; may vary elsewhere.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.  [Content Brief]

  [2]. PharmD CM, et al. Capecitabine: A review. Clinical Therapeutics. 2005 Jan; 27(1): 23-44.

  [3]. Guichard SM, et al. Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity. Eur J Cancer. 2008 Jan;44(2):310-7.  [Content Brief]